articleThe Lancet OncologySep 24, 2020Closed access

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

MPMariano ProvencioENErnest NadalAIAmelia InsaMRMaría Rosario García-CampeloJCJoaquín Casal‐Rubio

Hospital Universitario Puerta de Hierro Majadahonda · Institut Català d'Oncologia · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

819
total citations
FWCI
60.41
Percentile
100%
References
35
Citations per year

Authors

28

Topics & keywords

Topics
Keywords
  • Nivolumab
  • Medicine
  • Open label
  • Chemotherapy
  • Oncology
  • Lung cancer
  • Internal medicine
  • Neoadjuvant therapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding